Dual biologic therapy improves refractory Crohn’s disease, app reinforces colonoscopy preparation — top stories in gastroenterology
Click Here to Manage Email Alerts
A recent study showed that dual biologic therapy was linked to clinical and endoscopic improvements among patients with refractory Crohn’s disease. It was the top story in gastroenterology last week.
Another top story was about a smartphone application that helps patients adhere to colonoscopy preparations, resulting in better patient education, bowel cleanliness and adenoma detection.
Read these and more top stories in gastroenterology below:
Dual biologic therapy linked with clinical improvements in Crohn’s
Treatment with dual biologic therapy was associated with clinical and endoscopic improvements in patients with Crohn’s disease who previously failed multiple biologics, according to study results. Read more.
Smartphone app helps patients adhere to colonoscopy prep
A smartphone application helped reinforce patient education in the days preceding colonoscopy, resulting in better bowel cleanliness and adenoma detection, according to research published in Clinical Gastroenterology and Hepatology. Read more.
Dietary therapies induce rapid response in pediatric Crohn’s
Identifying which patients respond quickly to dietary therapies for Crohn’s disease may help indicate which ones will succeed long term and which ones might do better on a different therapy, according to study results. Read more.
VIDEO: Fellows graduating ready to perform procedures such as endoscopy
C. Jonathan D. Foster, DO, from the Jefferson Washington Township Hospital in New Jersey, said he thinks fellows who are graduating are ready to perform procedures such as advanced endoscopy. Watch video.
Delayed removal of swallowed button batteries in kids may further damage the stomach
Children who swallow button batteries are more likely to experience gastric damage if the object is removed 12 or more hours after ingestion, according to research published in Gastrointestinal Endoscopy. Read more.